)
)
Supernus Pharmaceuticals Investor Relations Material
Latest events
Q3 2024
Supernus Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Supernus Pharmaceuticals Inc
Access all reports
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its lead product candidate is Duopa (levodopa-carbidopa intestinal gel), a combination of levodopa and carbidopa for the treatment of Parkinson's disease in adults experiencing end-of-dose wearing off and end-of-dose dyskinesia; and ondansetron hydrochloride injectable suspension, which is being developed as a potential next generation form of treatment for chemotherapy-induced nausea and vomiting.
Key slides for Supernus Pharmaceuticals Inc
Study Update
Supernus Pharmaceuticals Inc
Status Update
Supernus Pharmaceuticals Inc
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
SUPN
Country
🇺🇸 United States